Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 68 of 82 for:    acne AND Acne Scars

Open-label, Prospective, Multicenter Study to Evaluate the Cutera Excel V™ Laser and a Micro-Lens Array Attachment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03424148
Recruitment Status : Recruiting
First Posted : February 6, 2018
Last Update Posted : March 15, 2018
Sponsor:
Information provided by (Responsible Party):
Cutera Inc.

Brief Summary:
Open-label, Prospective, Study to Evaluate the Cutera excel V laser at 532 nm in a low fluence, high repetition rate mode and the Micro-Lens Array attachment used with excel V laser at 1064 nm and 532 nm for the improvement of skin quality.

Condition or disease Intervention/treatment Phase
Scarring Skin Aging Device: Excel V™ Laser & Micro-Lens Array Attach Not Applicable

Detailed Description:
This is an open-label, prospective, study in approximately 60 male or female subjects, age 18 to 65 years who desire laser treatment for the improvement of rhytides, lentigines, pigmentation, erythema, telangiectasia, pore size and skin texture. Subjects may undergo a 2mm punch biopsy a treatment area up to 72 hours post treatment and at a designated follow-up period per Investigator discretion. Subjects will receive up to 6 laser treatments, spaced 6 weeks (± 4 weeks) apart. Subjects will be contacted by phone 7 days (± 2 days) after their first treatment for follow-up. Subjects will return to the site after final study treatment for two follow-up visits: 6 and 12 weeks (± 4 weeks).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Open-label, Prospective, Multicenter Study to Evaluate the Cutera Excel V™ Laser and a Micro-Lens Array Attachment
Estimated Study Start Date : March 2018
Estimated Primary Completion Date : November 2018
Estimated Study Completion Date : December 2018


Arm Intervention/treatment
Excel V™ Laser & Micro-Lens Array Attach
Treatment with Excel V™ Laser and a Micro-Lens Array Attachment for skin quality
Device: Excel V™ Laser & Micro-Lens Array Attach
Subjects will receive up to 6 laser treatments




Primary Outcome Measures :
  1. Measurement of device Adverse Effects (AE) [ Time Frame: through study completion, an average of 1 year ]
    Safety of the Cutera excel V™ laser and the Micro-Lens Array as assessed by the frequency and severity of device related adverse events.


Secondary Outcome Measures :
  1. Study Effectiveness for skin quality Improvement [ Time Frame: Baseline and Post treatment #2 through study completion, an average of 1 year ]
    Efficacy of treatment(s) with Cutera excel V™ laser and the Micro-Lens Array attachment as assessed by the study investigator using Skin Quality Rating Scale (1-10): for radiance, smoothness, pigmentation, erythema and pore size.

  2. Study Effectiveness for Improvement of Acne scarring severity [ Time Frame: Baseline and Post treatment through study completion, an average of 1 year ]
    Efficacy of treatment(s) with Cutera excel V™ laser and the Micro-Lens Array attachment as assessed by the study investigator using ASAS: Acne Scar Severity Assessment Scale (+1=clear, +2=very mild, +3=mild, +4=moderate, and +5=severe)

  3. Study Effectiveness for Improvement in wrinkle quantity and severity [ Time Frame: Baseline and Post treatment #2 through study completion, an average of 1 year ]
    Efficacy of treatment(s) with Cutera excel V™ laser and the Micro-Lens Array attachment as assessed by the study investigator using FWCS: Fitzpatrick Wrinkle Classification System (1-3=fine wrinkles, 4-6=moderate depth & moderate number of lines, 7-9 severe depth & numerous lines)

  4. Study Effectiveness for skin aesthetic Improvement [ Time Frame: Post treatment #2 through study completion, an average of 1 year ]
    Efficacy of treatment(s) with Cutera excel V™ laser and the Micro-Lens Array attachment as assessed by the study investigator using GAIS: Global Aesthetic Improvement Scale (+4=Very Significant Improvement (=or>75), +3=Significant Improvement (50-74%), +2=Moderate Improvement (25-49%), +1=Mild Improvement (5-24%) or 0=No Change (<5%))



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Subject must be able to read, understand and sign the Informed Consent Form.
  2. Female or Male, 18 to 65 years of age (inclusive).
  3. Fitzpatrick Skin Type I - VI.
  4. Must be willing to have Cutera excel V laser treatments and able to adhere to the treatments, follow-up visit schedule, and post-treatment care instructions.
  5. Willing to have very limited sun exposure and use sunscreen on the treatment area every day for the duration of the study, including the follow-up period.
  6. Willing to have digital photographs taken of the treatment area and agree to use of photographs for presentation (educational and/or marketing), publications, and any additional marketing purposes.
  7. Agree to not undergo any other cosmetic procedure(s) or treatment(s) on the face during the study and has no intention of having such procedures performed during the course of the study.
  8. For female subjects: not pregnant or lactating and is either post-menopausal, surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course of the study.,

Exclusion Criteria:

  1. Participation in a clinical trial of another drug, or device administered to the treatment area, within 3 months prior to enrollment or during the study.
  2. Any type of prior cosmetic treatment to the target area within 6 months of study participation, such as laser procedures, facial fillers, toxins and those used for general aesthetic correction.
  3. Use of prescription topicals in the treatment area within one month prior to treatment or use of topical agents one week prior to treatment that may cause facial sensitivity.
  4. Suffering from significant skin conditions in the treated areas or inflammatory skin conditions, including but not limited to, open lacerations or abrasions, hidradenitis, rash, infection , or dermatitis of the treatment area prior to treatment (duration of resolution as per the Investigator's discretion).
  5. Pregnant and/or breastfeeding, or planning to become pregnant.
  6. Significant concurrent illness, such as diabetes mellitus, immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or using immunosuppressive medication.
  7. Hypersensitivity to light exposure.
  8. Any use of medication that is known to increase sensitivity to light according to the Investigator's discretion.
  9. History of keloid scarring, hypertrophic scarring or abnormal wound healing or prone to bruising.
  10. Has a history of squamous cell carcinoma or melanoma in the treatment area.
  11. History of epidermal or dermal disorders (particularly if involving collagen or microvascularity), including collagen vascular disease or vasculitic disorders.
  12. A history or active skin condition that in the opinion of the Investigator may interfere/confound with the treatment.
  13. History of connective tissue disease, such as systemic lupus erythematosus or scleroderma.
  14. History of disease stimulated by heat, such as recurrent herpes simplex and/or herpes zoster (shingles) in the treatment area, unless treatment is conducted following a prophylactic regimen.
  15. History of pigmentary disorders, particularly tendency for hyper- or hypo-pigmentation, or any that are considered not acceptable by the study investigator.
  16. Has used oral isotretinoin (Accutane or therapeutic vitamin A supplements of ≥ 10,000 units per day) within 12 months of initial treatment or plans on using during the course of the study (note: skin must regain its normal degree of moisture prior to treatment, e.g. lack of noticeable skin flaking and peeling).
  17. Excessively tanned or active sun tan in facial area to be treated, or unable/unlikely to refrain from tanning during the study.
  18. Excessive facial hair in the area to be treated (beards, sideburns, and/or moustache,) that would interfere with diagnosis, assessment, and treatment.
  19. As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study, including excessive alcohol or drug abuses, or a condition that would compromise the subject's ability to comply with the study requirements.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03424148


Contacts
Layout table for location contacts
Contact: Michaela Bell 415-657-5722 mbell@cutera.com
Contact: Ginger Pocock 415-657-5702 gpocock@cutera.com

Locations
Layout table for location information
United States, California
Cutera Research Center Recruiting
Brisbane, California, United States, 94005
Contact: Mischell San Juan    415-657-5544    msanjuan@cutera.com   
Principal Investigator: Stephen Ronan, M.D.         
Center for Dermatology and Laser Surgery Recruiting
Sacramento, California, United States, 95819
Contact: Susan    916-454-5922    susan@dermatologyandlasersurgery.com   
Contact: Julie    916-454-5922    julie@dermatologyandlasersurgery.com   
Principal Investigator: Emil Tanghetti, MD         
Sponsors and Collaborators
Cutera Inc.

Layout table for additonal information
Responsible Party: Cutera Inc.
ClinicalTrials.gov Identifier: NCT03424148     History of Changes
Other Study ID Numbers: C-17-EV11
First Posted: February 6, 2018    Key Record Dates
Last Update Posted: March 15, 2018
Last Verified: September 2017

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes

Additional relevant MeSH terms:
Layout table for MeSH terms
Chlorhexidine
Chlorhexidine gluconate
Anti-Infective Agents, Local
Anti-Infective Agents
Disinfectants
Dermatologic Agents